UNSPSC 51432704: Flordipine

This classification denotes a calcium channel blocker with the molecular formula C26H33F3N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8UFI7XI7R, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-1-(2-(4-morpholinyl)ethyl)-4-(2-(trifluoromethyl)phenyl)-, diethyl ester but generally known as flordipine, which bears US NIH Compound Identifier 53699. European Medicines Agency schedules Flordipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07649MIG.

UNSPSC 51432704 Flordipine, a Commodity code, represents pharmaceutical products that state and local governments procure for emergency medical services, health agency programs, and cooperative purchasing networks. Recent solicitations show state and local buyers acquiring advanced life support medications and generic pharmaceuticals through competitive sealed bids and cooperative purchasing agreements, with vendors required to meet strict FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and expiration-date requirements. The City of Tampa's Fire Rescue division, the Texas Health and Human Services Commission, and multistate cooperative purchasing alliances all source medications through this code, reflecting procurement across municipal emergency services, state health agencies, and cooperative purchasing vehicles that serve multiple jurisdictions.

State and local activity under the code spans Florida, Texas, and the multistate cooperative purchasing network anchored in Minnesota and extending to Oregon. The City of Tampa issued an IFB (Bid No. 26P00188) due April 8, 2026, for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials, valued at $40,000, with a one-year contract term and options for renewal; the solicitation included a Small Local Business Enterprise (SLBE) sheltered market designation with a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to supply participating state and local facilities across multiple states, with contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness and 25 percent on compliance and operational criteria. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on March 27, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling preliminary exploration of direct contracting models outside traditional pharmacy benefit manager channels.